Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > ARCHIVE
ARCHIVE
- Aiming at Drug Sales of \320 Billion in 2004: Mr Bootes of Pfizer
March 19, 2001
- Videx Cap. Included in NHI Price List on Emergency Basis
March 19, 2001
- JPA to Conduct Survey of Endocrine Disruptors
March 19, 2001
- Generics Approved by March 15 to Be Given NHI Prices in July
March 19, 2001
- JPMA to Prepare Guidebooks on New PMS Requirements
March 19, 2001
- LDP Intends to Deal with NHI Prices at First
March 19, 2001
- Kyowa Hakko Aims at Peak Sales of \20 Bil. for Allelock
March 19, 2001
- Need for Self-sufficient Blood Supply System Stressed Again: Red Cross Symposium
March 19, 2001
- Korosho to Promote Studies to Set Pediatric Doses
March 19, 2001
- Chuikyo Approves 3 New Advanced Medical Technologies
March 19, 2001
- Control Achieved in More than 65% of RA Patients in Long-term Outpatient Care: RDIC Seminar
March 19, 2001
- Notification Issued on ICH Stability Test Guidelines
March 19, 2001
- Significance of Genomic Base Sequence Other than Gene Code Should Be Studied: Prof. Shimizu
March 19, 2001
- REGULATORY NEWS IN BRIEF -1-
March 19, 2001
- PMSB to Issue Notification on Safety Management of Medical Radiation
March 19, 2001
- OTC NEWS IN BRIEF
March 12, 2001
- Nicorette Reexamined, 2 New Orphan Drugs Designated
March 12, 2001
- Sankyo Aims at \1 Trillion Sales in FY2010: President Takato
March 12, 2001
- Q&A Booklet on New PMS for 6 Months after Launching Issued
March 12, 2001
- MTP Ties Up with Sumitomo, MedGene Regarding HGF
March 12, 2001
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…